inLife LLC releases its range of 4 branded starter kits at the low price of $29.95, a 60% saving over its previous starter kit pricing.

Save even more money and get your starter kit for free when you commit to a minimum cartridge order purchase.

The four brands include the Standard regal2 e-cig in silver with USB charger and two high cartridges.

The inLife Regal 2 Menthol Pack also includes USB charger and two menthol high cartridges

The She Vapes For Girls

this includes a pink battery, USB charger and two cartridges, one cherry flavoured and one standard high.

And finally, the all new NicMaxx, max nicotine (3.5%). This is double the percentage nicotine than the standard high cartridge. For the heavy smoker who needs that extra bit of help transitioning from tobacco!

All For $29.95 each (or FREE with cartridge purchase commitment)

If you purchase 10 bottles of inForce Platinum as a distributor you would pay $735.54, a $92 saving on the same purchase as a retail customer.

To join just follow the ‘JOIN‘ page above. Select your country and on the second page, scroll to the bottom to find the FREE distributor option.

Once enrolled, go to your back office shop to purchase product at wholesale.

Coriolus PSP extracted under the process patented by Dr Yang is the same as that used in many of the medical studies published by hospitals and universities around the world. See Medical Studies

PSP, Polysaccahride Peptide, is an ethanol extraction from the mycelium stage of the Coriolus Versicolor mushroom.

Prostate Cancer & PSP

Recent evidence suggested that prostate cancer stem/progenitor cells (CSC) are responsible for cancer initiation as well as disease progression. Unfortunately, conventional therapies are only effective in targeting the more differentiated cancer cells and spare the CSCs. Here, we report that PSP, an active component extracted from the mushroom Turkey tail (also known as Coriolus versicolor), is effective in targeting prostate CSCs. We found that treatment of the prostate cancer cell line PC-3 with PSP led to the down-regulation of CSC markers (CD133 and CD44) in a time and dose-dependent manner. Meanwhile, PSP treatment not only suppressed the ability of PC-3 cells to form prostaspheres under non-adherent culture conditions, but also inhibited their tumorigenicity in vivo, further proving that PSP can suppress prostate CSC properties. To investigate if the anti-CSC effect of PSP may lead to prostate cancer chemoprevention, transgenic mice (TgMAP) that spontaneously develop prostate tumors were orally fed with PSP for 20 weeks. Whereas 100% of the mice that fed with water only developed prostate tumors at the end of experiment, no tumors could be found in any of the mice fed with PSP, suggesting that PSP treatment can completely inhibit prostate tumor formation. Our results not only demonstrated the intriguing anti-CSC effect of PSP, but also revealed, for the first time, the surprising chemopreventive property of oral PSP consumption against prostate cancer.

Anti Tumour Effect Of PSP

PSP, the protein-bound polysaccharide, extracted from a strain of Coriolus versicolor (Cov-1) by Professor Qing-yao Yang, has been proved to be effective against tumor both in animal experiments and in clinical patients. Previous results suggested that the antitumor effects of PsP were related to the potentiation of immunological responses, especially T-cell mediated immune responses of tumorbearing hosts. Since T-lymphocytes play an important role in immune response and T-cell deficiency existed in many diseases, the most noticeable one at present time is the acquired immune deficient syndrome (AIDS) which leads to the failure of T-cell functions and death. Until now there is not any effective drug in curing this disease.

It is of great interest to investigate if PSP can potentiate T-cell functions and restore the immune deficient conditions in tumor, AIDS and other viral infections. In this paper both in vivo and in vitro experiments were used to study PSP on:

1) immune organ weights,

2) antibody informations,

3) serum complement contents,

4) T lymphocyte proliferations,

5) interleukin-2 production,

6) delayed type hypersensitivity reaction,

7) phagocytic ability of reticulo-endothelial system and

Protection of liver injuries from CCl4 intoxication.

Source (mushroomstudies.com)

Pharmacodynamic studies prove that PSP has a very obvious effect of strengthening health and energy to eliminate substances and is a new type of BRM (Biological response Modifier)

(Source: http://psp-research.com)

Buy 100% PSP (Dr Yang extraction) inForce Platinum or go to shop above.

We found this interesting article regarding physiological effects of Coriolus Versicolor PSP. Most of the references use the Dr Yang extraction PSP that can be bought in the form of inForce Platinum by inLife llc or by visiting the inForce shop. Just click the SHOP link above.

• Promotes the proliferation of T cells and pre-T cells.
• Increases thymus weight.
• Increases the biological effects of radiation.
• Possesses direct cytotoxic effects to tumor cells and inhibits tumor growth.
• Increases the production of IL-2, IgG, C3, and interferon.
• Raises the activities of NK cells and macrophages.
• Maintains and raises white blood cell count.
• Lessens the side effects of chemotherapy and radiotherapy.
• Reduces pain in terminal patients.
• Prevents liver injuries induced by CCl4 (carbon-tetrachloride-based drugs).

References

Yang QY, Yong SC, Yang XT.  The physio-chemical characteristics of the polysaccharide-peptide (PSP) of Coriolus versicolor (Yun Zhi).  In: Report on the polysaccharide-peptide (PSP) of Coriolus versicolor, 1987: pp1-6.  Landford.  China.

Liu WK, Ng TB, Sze SF, Tsui KW.  Activation of peritoneal macrophages by polysaccharopeptide from the mushroom Coriolus versicolor.  Immunopharmacology 1993; 26: 139-146.

Dong Y, Kwan CY, ChenZN, Yang MMP.  Antitumor effects of a refined polysaccharide peptide fraction isolated from Coriolus versicolor: in vitro and in vivo studies.  Research communication in Molecular Pathology and Pharmacology 1996, 92(2): 140-148.

Yang QY, Yan P.  Isolation of the polysaccharide components of PSP.  J. Shanghai Teach. Univ. (Natural Sciences Ed.) 1986; 4: 36.

Liu TF, Xue WC.  Clinical implication of PSP in oncology.  In: Recent Advances in Cancer, published by Cancer Research Group, CUHK, 1989: 57-62.

Li SM, Xu LZ.  A study of anti-cancer effects of PSP and PSK on human tumor cell lines in vitro.  Acta Acad. Med., Shanghai, 1987, 14: 23-24.

Zhou JX, Li XY, Shen XL.  The anti-tumor and immunomodulating activity of PSP in mice.  J. Shanghai Teach. Univ. (Natural Sciences Ed.) 1988, 3:72.

Li SY, Wang JF.  Immuno-modulating actions of PSP.  In: Recent Advances in Cancer, published by Cancer Research Group, CUHK, 1989: 45-56.

Li XY, Wang JF, Zhu PP, Ge JB, Yang SX.  Immune enhancement of polysaccharides peptides isolated from Coriolus versicolor.  Acta Pharm. Sinica 1990, 11: 542-45.

Yang MMP, Chen ZN, Kwok JSL.  The anti-tumor effect of a small polypeptide from Coriolus versicolor.  American J. Chinese Med. 1992, 20: 221-232.

Shiu WCT, Leung TWT, Tao M.  A clinical study of PSP on peripheral blood counts during chemotherapy.  Phytotherapy Res. 1992, 6: 217.

Xue WC, Liu TF.  Clinical experience in the use of PSP.  Cancer Hospital, Shanghai Medical University.

Sun ZY, et al.  The preliminary appraisal of polysaccharide peptide (PSP) in malignant and non-malignant diseases.  Shanghai Medical University.

Zhou JX, Shen XL, Shen ZM, Li XY.  Antitumor effect of polysaccharide peptide of Coriolus versicolor (PSP) and its mechanism.  Department of Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Science, Shanghai, China.

(Source: www.naturodoc.com)

The government’s “nudge unit” wants to encourage the use of smokeless nicotine cigarettes, banned in many countries around the world, in an attempt to reduce the numbers killed in the UK by smoking diseases each year.

The Cabinet Office’s behavioural insight team – better known as the nudge unit – wants to adopt the new technology because policy officials believe the rigid “quit or die” approach to smoking advice no longer works. Rather, they want nicotine addiction to be managed to help smokers who otherwise won’t quit – an approach the unit believes could prevent millions of smoking deaths. Ten million people in the UK smoke, and smoking claims 80,000 lives a year.

The nudge unit’s first annual report, published on Thursday, says the unit – the first of its kind around the world – has, in the face of criticism, implemented a series of measures they believe could save thousands of lives a year, as well as £100m over the course of the next parliament.

Ideas already being rolled out include “nudging” people to donate organs by asking someone to opt out rather than opt in when filling out an online driving licence application. The report also says the government is to change tax forms to tell people how many people in their area have paid their taxes ahead of them.

Now the unit wants to explore and encourage new products that deliver nicotine to people’s lungs but without the harmful toxins and carcinogens in tobacco smoke that kill.

The annual report reads: “It will be important to get the regulatory framework for these products right, to encourage new products. A canon of behaviour change is that it is much easier to substitute a similar behaviour than to extinguish an entrenched habit (an example was the rapid switch from leaded to unleaded fuel). If alternative and safe nicotine products can be developed which are attractive enough to substitute people away from traditional cigarettes, they could have the potential to save 10,000s of lives a year.”

Current alternatives to smoking range from smokeless tobacco to the Swedish snuff-like product Snus, which is illegal in the UK. Versions of smoke-free cigarettes are illegal in Australia, and banned in Canada, Brazil, Singapore and Thailand because side-effects haven’t been tested.

But experts have advised the UK government that the nicotine contained in some new, smoke-free cigarettes is no more harmful than caffeine in coffee. A Cabinet Office source said: “A lot of countries are moving to ban this stuff; we think that’s a mistake.”

John Britton, professor of epidemiology at the University of Nottingham, told the Guardian that on top of the current smokeless range – which includes electronic or “e-cigarettes” that simulate smoking by producing an inhaled mist – there are three or four devices in different stages of development. But he said some companies have been reluctant to develop this technology because they had expected it to be as tightly controlled as pharmaceutical drugs.

Britton said: “If a manufacturer makes a health claim for anything then it becomes a drug, and drugs have to be regulated with tight controls. The current nicotine replacements are sold as drugs; however, e-cigarettes contain nicotine but get around this by making no health claim and so can be sold freely, but with little or no information on safety or standards. What we’re asking for is a regulation change to bring all nicotine products into a light-touch regime that will guarantee reasonable purity and safety standards but make them as available as cigarettes in a shop.”

The Medicine and Healthcare Products Regulatory Agency (MHRA) is looking into approving these devices for use. If it finds in their favour, the government is likely to push for them to be placed prominently in shops alongside tobacco cigarettes, where they would be sold at a cheaper rate.

The unit is keen to engage with those critics who believe its analysis and intervention in people’s behaviour is “nanny statism”.

David Halpern, the unit’s head, told the Guardian: “As with seatbelts and the smoking ban, these ideas were unpopular at first but after a while when you explain them to people, they understand and say, ‘Yeah, alright then.’

“A year in,” Halpern added, “we’re much more confident about how well this can work, and the early trials have also made us much more confident about public acceptability. There’s no doubt it can save many lives and hundreds of millions of pounds. In fact, our problem has become that we have so many inquiries from across Whitehall, we have to turn down many of the requests for help.”

Original post: www.guardian.co.uk

The government’s “nudge unit” wants to encourage the use of smokeless nicotine cigarettes, banned in many countries around the world, in an attempt to reduce the numbers killed in the UK by smoking diseases each year.

The Cabinet Office’s behavioural insight team – better known as the nudge unit – wants to adopt the new technology because policy officials believe the rigid “quit or die” approach to smoking advice no longer works. Rather, they want nicotine addiction to be managed to help smokers who otherwise won’t quit – an approach the unit believes could prevent millions of smoking deaths. Ten million people in the UK smoke, and smoking claims 80,000 lives a year.

The nudge unit’s first annual report, published on Thursday, says the unit – the first of its kind around the world – has, in the face of criticism, implemented a series of measures they believe could save thousands of lives a year, as well as £100m over the course of the next parliament.

Ideas already being rolled out include “nudging” people to donate organs by asking someone to opt out rather than opt in when filling out an online driving licence application. The report also says the government is to change tax forms to tell people how many people in their area have paid their taxes ahead of them.

Now the unit wants to explore and encourage new products that deliver nicotine to people’s lungs but without the harmful toxins and carcinogens in tobacco smoke that kill.

The annual report reads: “It will be important to get the regulatory framework for these products right, to encourage new products. A canon of behaviour change is that it is much easier to substitute a similar behaviour than to extinguish an entrenched habit (an example was the rapid switch from leaded to unleaded fuel). If alternative and safe nicotine products can be developed which are attractive enough to substitute people away from traditional cigarettes, they could have the potential to save 10,000s of lives a year.”

Current alternatives to smoking range from smokeless tobacco to the Swedish snuff-like product Snus, which is illegal in the UK. Versions of smoke-free cigarettes are illegal in Australia, and banned in Canada, Brazil, Singapore and Thailand because side-effects haven’t been tested.

But experts have advised the UK government that the nicotine contained in some new, smoke-free cigarettes is no more harmful than caffeine in coffee. A Cabinet Office source said: “A lot of countries are moving to ban this stuff; we think that’s a mistake.”

John Britton, professor of epidemiology at the University of Nottingham, told the Guardian that on top of the current smokeless range – which includes electronic or “e-cigarettes” that simulate smoking by producing an inhaled mist – there are three or four devices in different stages of development. But he said some companies have been reluctant to develop this technology because they had expected it to be as tightly controlled as pharmaceutical drugs.

Britton said: “If a manufacturer makes a health claim for anything then it becomes a drug, and drugs have to be regulated with tight controls. The current nicotine replacements are sold as drugs; however, e-cigarettes contain nicotine but get around this by making no health claim and so can be sold freely, but with little or no information on safety or standards. What we’re asking for is a regulation change to bring all nicotine products into a light-touch regime that will guarantee reasonable purity and safety standards but make them as available as cigarettes in a shop.”

The Medicine and Healthcare Products Regulatory Agency (MHRA) is looking into approving these devices for use. If it finds in their favour, the government is likely to push for them to be placed prominently in shops alongside tobacco cigarettes, where they would be sold at a cheaper rate.

The unit is keen to engage with those critics who believe its analysis and intervention in people’s behaviour is “nanny statism”.

David Halpern, the unit’s head, told the Guardian: “As with seatbelts and the smoking ban, these ideas were unpopular at first but after a while when you explain them to people, they understand and say, ‘Yeah, alright then.’

“A year in,” Halpern added, “we’re much more confident about how well this can work, and the early trials have also made us much more confident about public acceptability. There’s no doubt it can save many lives and hundreds of millions of pounds. In fact, our problem has become that we have so many inquiries from across Whitehall, we have to turn down many of the requests for help.”

Original post: www.guardian.co.uk

Coriolus PSP extracted under the process patented by Dr Yang is the same as that used in many of the medical studies published by hospitals and universities around the world. See Medical Studies

PSP, Polysaccahride Peptide, is an ethanol extraction from the mycelium stage of the Coriolus Versicolor mushroom.

Coriolus PSP - inForce Platinum

A few years ago PSP was an extremely expensive remedy but thanks to it rising popularity the price has now reduced to affordable levels.

Buy inForce Platinum – Click here

For More Information on inForce Platinum – Click Here

Any smoker wanting to smoke sitting at the bar can purchase a PIF starter e-cig and the cartridge it comes with along with the USB charger means that they can smoke all night and then recharge via their laptop or computer when they get home.

This finally produces a great revenue source for the bar or club as they not only make a profit on the unit sale (RRP being $19.95) and 10 kits available for $99, but will also make a residual income from either stocking cartridges themselves or by sales through the website provided for them by inLife.

The ‘already charged’ device replaces the need for customers to charge the batteries for 8 hours first time before using it. This deflected being able to provide a device that worked at ‘point of need’

The new devices which are a fraction of the cost of the old regal 2 starter kits means the need can be met on the spot for a price that is less than the price of a couple of packs of tobacco cigarettes in most states.